Search | Clinical Trials Finder

Conditions: Vitiligo
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 26
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Rogers, Arkansas + 21 more

Conditions: Cutaneous Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma
Interventions: Eutectic Mixture of Local Anesthetics, Placebo Administration, Questionnaire Administration; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Female Sexual Health
Interventions: Sildenafil; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Female Sexual Dysfunction
Interventions: arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%, Topical study cream, GRAS cream; Drug
Lead sponsor: East Suburban Ob Gyn; Other
Eligibility: 25 Years to 60 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Monroeville, Pennsylvania

Conditions: Plaque Psoriasis
Interventions: Roflumilast; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: Beverly Hills, California • Northridge, California • San Diego, California + 16 more

Conditions: Atopic Dermatitis
Interventions: 1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2; Drug
Lead sponsor: Amytrx Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Cerritos, California • Encino, California • Long Beach, California + 8 more

Conditions: Adult Brain Glioblastoma, Glioblastoma Multiforme
Interventions: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more

Conditions: Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions: Alprostadil, Placebo; Drug · Other
Lead sponsor: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.); Industry
Eligibility: 18 Years to 79 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: SRD174 Cream, vehicle cream; Drug · Other
Lead sponsor: Serentis Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 13
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Oceanside, California + 10 more

Conditions: Eczema
Interventions: hydrogel patch, Triamcinolone (TAC) 0.1% cream; Device · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Radiodermatitis
Interventions: Difinsa53, Aquaphor; Drug
Lead sponsor: ProTechSure Scientific, Inc.; Industry
Eligibility: Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Dermatitis, Atopic
Interventions: VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P; Drug · Other
Lead sponsor: Vitae Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: West Dundee, Illinois • Fort Gratiot, Michigan • New York, New York + 2 more

Conditions: Genital Warts
Interventions: 2.5% imiquimod cream, 3.75% imiquimod cream, Placebo cream; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 43
States / cities: Jonesboro, Arkansas • Carmichael, California • Chico, California + 35 more

Conditions: Forehead Rhytides, Forehead Wrinkles
Interventions: Botulinum toxin type A, 2.5% lidocaine/2.5% prilocaine, petrolatum ointment; Drug · Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pompe Disease
Interventions: Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream; Genetic · Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Acne Vulgaris
Interventions: clindamycin phosphate 1.2% and tretinoin 0.025%, clindamycin 1% gel, tretinoin 0.025% cream; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 12 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Tinea Cruris, Tinea Pedis
Interventions: UHE-103 Cream, Naftin (naftifine hydrochloride) Cream; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: San Diego, California • Thousand Oaks, California • Austin, Texas + 2 more

Conditions: Facial Wrinkles at the Nasolabial Folds
Interventions: Dermal Gel Extra (DGE), Restylane, EMLA Cream; Device · Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Birmingham, Alabama • La Jolla, California • Miami Beach, Florida + 3 more

Conditions: Pregnancy Related, Atopic Dermatitis
Interventions: Ruxolitinib Cream, TCS; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 14 Years and older · Female only
Enrollment: 5,621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Dermatitis, Atopic, Eczema
Interventions: Investigational OTC Cream, Cosmetic Eczema Cream, 0.05% Desonide Cream, Placebo Cream; Drug · Other
Lead sponsor: Procter & Gamble Beauty; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Restless Legs Syndrome
Interventions: Chylobinoid Topical Cream; Drug
Lead sponsor: Synthonics Inc; Industry
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Sarasota, Florida

Conditions: Acne Vulgaris
Interventions: UHE-101 Cream, Vehicle Cream; Drug · Other
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Palmar-Plantar Erythrodysesthesia, Breast Cancer
Interventions: Cream, 0.1% Uracil Cream; Drug
Lead sponsor: Nanometics (d.b.a. PHD Biosciences); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Birmingham, Alabama • Palm Springs, California • Evansville, Indiana + 3 more

Conditions: Papulopustular Rosacea (PPR)
Interventions: CD5024, Azelaic acid 15% Gel; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 40
States / cities: Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more

Search by objective public record fields.

A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

Assessing the Effects of a Topically Applied Cream to Clitoral Blood Flow

Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

Hydrogel Patch for the Treatment of Eczema

Topical Use of Difinsa53™ to Prevent Radiation Dermatitis

An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

Botulinum Toxin Type A Injection After Topical Anesthesia Versus Petrolatum Ointment

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis

Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome

Phase 3 Papulopustular Rosacea Study